QuidelOrtho Corporation (QDEL)

40,11 +0,42 (+1,06 %) À partir de 12:17PM EDT. Marché ouvert.

QuidelOrtho Corporation

9975 Summers Ridge Road
San Diego, CA 92121
United States
858 552 1100
https://www.quidelortho.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 7 100

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Michael S. Iskra	Interim CEO, Executive VP & Chief Commercial Officer	870,93k	S.O.	1970
Mr. Robert J. Bujarski J.D.	Interim President, Executive VP & COO	961,26k	S.O.	1969
Mr. Joseph M. Busky CPA	Chief Financial Officer	890,63k	S.O.	1968
Dr. Werner Kroll Ph.D.	Senior Vice President of Research & Development	1,03M	S.O.	1957
Ms. Louise M. Brandy	Chief Information Officer	S.O.	S.O.	1959
Ruben Argueta	Director of Investor Relations	S.O.	S.O.	S.O.
Ms. Michelle A. Hodges J.D.	Senior VP, General Counsel & Corporate Secretary	1,8M	S.O.	1963
Mr. William J. Ferenczy	Point of Care Business Unit Leader	S.O.	S.O.	1956
Ms. Tamara A. Ranalli	Molecular Diagnostics Business Unit Leader	S.O.	S.O.	1973

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de QuidelOrtho Corporation en date du 1 avril 2024 est 3. Les scores principaux sont Audit : 6; Société : 2; Droits des actionnaires : 4; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.